The U.S. Drug Enforcement Administration (DEA) has initiated significant steps towards issuing a temporary scheduling order for specific kratom-based products, a move that carries substantial implicat

The U.S. Drug Enforcement Administration (DEA) has initiated significant steps towards issuing a temporary scheduling order for specific kratom-based products, a move that carries substantial implications for merchants and consumers within the industry. The focus of this action is on products containing high levels of 7-hydroxymitragynine (7-OH) and related synthetic components.

DEA Targets High-7-OH and Synthetic Kratom Products

On July 1, 2026, the DEA filed two Federal Register notices signaling its intent to temporarily place 7-OH, when present above a specified threshold, and three synthetic 7-OH derivatives—mitragynine pseudoindoxyl, MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act (CSA). This decision follows assessments by the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA), which concluded that these specific kratom-related synthetic substances have no accepted medical use and possess a high potential for abuse.

The Attorney General holds the authority to issue such a temporary scheduling order, which would typically remain in effect for two years, with a potential one-year extension, if deemed necessary to address an imminent hazard to public safety.

Why This Matters to Kratom Merchants and Consumers

This proposed scheduling is critically important as it draws a clear distinction between naturally occurring botanical kratom and products that are either adulterated or synthetically enhanced. While 7-OH is a natural alkaloid found in kratom leaves, it typically exists in very small, trace amounts, often less than 0.05% or 0.02% of the dry weight.

However, the market has seen a "proliferation" of commercial products containing significantly higher levels of 7-OH, often synthesized in laboratories or derived semi-synthetically. These concentrated and synthetic forms are considerably more potent than traditional kratom and are associated with a heightened risk of tolerance, dependence, withdrawal, and overdose.

For consumers, this means that products explicitly marketed as kratom but containing these high concentrations of synthetic or artificially elevated 7-OH will become federally illegal. For merchants, a Schedule I classification is severe, imposing stringent regulatory controls and significant administrative, civil, and criminal penalties on anyone involved in the manufacture, distribution, import, export, or possession of these now-controlled substances.

Compliance Implications for High-Risk Merchants

Given this impending regulatory action, high-risk kratom merchants must immediately review and adjust their compliance strategies:

1. Mandatory Third-Party Lab Testing: It is no longer sufficient to merely test for basic alkaloid content. Merchants must implement rigorous, independent third-party lab testing for all products. These tests must accurately identify and quantify the full alkaloid profile, specifically distinguishing between naturally occurring 7-OH and any elevated or synthetic forms. The DEA's action specifically targets products with "higher than naturally occurring 7-OH or mitragynine or synthetic 7-OH related substances." Merchants must ensure their products fall below any established threshold for 7-OH.
2. Transparency with COAs: Make Certificates of Analysis (COAs) readily accessible to both consumers and business partners. This transparency is crucial for demonstrating due diligence and a commitment to providing safe, compliant products.
3. Scrutinize Product Formulations: Merchants should meticulously review their entire product catalog, especially extracts, enhanced powders, gummies, and liquid shots, which are frequently found to contain elevated or synthetic 7-OH. Any product containing synthetic 7-OH derivatives or levels of 7-OH exceeding natural thresholds must be immediately removed from sale.
4. Stay Abreast of Regulations: The legal landscape for kratom is constantly evolving. Merchants must stay informed about federal and state laws, understanding that a federal Schedule I classification will supersede state-level regulations, including Kratom Consumer Protection Acts (KCPAs), for the scheduled compounds.
5. Anticipate Payment Processing Challenges: This heightened federal scrutiny will likely lead to increased vigilance from payment processors and banking institutions. Merchants found to be dealing in federally scheduled substances could face account terminations or significant challenges in securing financial services. Proactive compliance is the most effective way to mitigate such risks.

This DEA action serves as a critical reminder that the kratom industry must prioritize product integrity, transparent labeling, and stringent quality control. Adhering to these principles is not just a matter of best practice, but an increasingly vital legal and operational imperative.